Alterity Therapeutics Limited (ATH.AX)
AUD 0.01
(14.29%)
AUD 0.01
(14.29%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -19.12 Million AUD | -38.51% |
| 2023 | -13.8 Million AUD | -7.47% |
| 2022 | -12.84 Million AUD | 16.08% |
| 2021 | -15.3 Million AUD | -57.87% |
| 2020 | -9.69 Million AUD | 18.93% |
| 2019 | -11.96 Million AUD | -44.72% |
| 2018 | -8.26 Million AUD | -9.59% |
| 2017 | -7.54 Million AUD | 2.43% |
| 2016 | -7.72 Million AUD | -31.34% |
| 2015 | -5.88 Million AUD | 55.85% |
| 2014 | -13.32 Million AUD | -71.17% |
| 2013 | -7.78 Million AUD | -48.63% |
| 2012 | -5.23 Million AUD | 18.53% |
| 2011 | -6.43 Million AUD | -31.06% |
| 2010 | -4.9 Million AUD | 34.77% |
| 2009 | -7.52 Million AUD | 44.64% |
| 2008 | -13.58 Million AUD | -21.99% |
| 2007 | -11.14 Million AUD | 5.0% |
| 2006 | -11.72 Million AUD | 52.92% |
| 2005 | -24.9 Million AUD | -153.49% |
| 2004 | -9.82 Million AUD | -114.94% |
| 2003 | -4.57 Million AUD | 16.15% |
| 2002 | -5.45 Million AUD | -31.71% |
| 2001 | -4.13 Million AUD | -212.07% |
| 2000 | -1.32 Million AUD | -1557.86% |
| 1999 | -80 Thousand AUD | -11494.2% |
| 1998 | -690.00 AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q4 | -12.61 Million AUD | 0.0% |
| 2024 FY | -19.12 Million AUD | -38.51% |
| 2024 Q2 | -6.5 Million AUD | 0.0% |
| 2023 FY | -13.8 Million AUD | -7.47% |
| 2023 Q4 | -5.77 Million AUD | 0.0% |
| 2023 Q2 | -8.03 Million AUD | 0.0% |
| 2022 Q4 | -6.26 Million AUD | 0.0% |
| 2022 Q2 | -6.58 Million AUD | 0.0% |
| 2022 FY | -12.84 Million AUD | 16.08% |
| 2021 FY | -15.3 Million AUD | -57.87% |
| 2021 Q4 | -6.74 Million AUD | 0.0% |
| 2021 Q2 | -8.56 Million AUD | 0.0% |
| 2020 Q1 | -2.82 Million AUD | 59.7% |
| 2020 FY | -9.69 Million AUD | 18.93% |
| 2020 Q2 | -5.64 Million AUD | -100.0% |
| 2020 Q3 | -3.9 Million AUD | 30.71% |
| 2020 Q4 | -7.81 Million AUD | -100.0% |
| 2019 Q3 | -3.49 Million AUD | 34.48% |
| 2019 Q1 | -2.67 Million AUD | 42.56% |
| 2019 Q4 | -6.99 Million AUD | -100.0% |
| 2019 FY | -11.96 Million AUD | -44.72% |
| 2019 Q2 | -5.34 Million AUD | -100.0% |
| 2018 Q3 | -2.32 Million AUD | 35.75% |
| 2018 Q2 | -3.61 Million AUD | -100.0% |
| 2018 FY | -8.26 Million AUD | -9.59% |
| 2018 Q4 | -4.64 Million AUD | -100.0% |
| 2018 Q1 | -1.8 Million AUD | 53.51% |
| 2017 Q1 | -1.82 Million AUD | 62.54% |
| 2017 Q3 | -1.94 Million AUD | 46.74% |
| 2017 Q2 | -3.65 Million AUD | -100.0% |
| 2017 FY | -7.54 Million AUD | 2.43% |
| 2017 Q4 | -3.89 Million AUD | -100.0% |
| 2016 Q4 | -4.87 Million AUD | -100.0% |
| 2016 Q2 | -2.85 Million AUD | -100.0% |
| 2016 Q3 | -2.43 Million AUD | 14.62% |
| 2016 Q1 | -1.42 Million AUD | 69.19% |
| 2016 FY | -7.72 Million AUD | -31.34% |
| 2015 FY | -5.88 Million AUD | 55.85% |
| 2015 Q2 | -1.25 Million AUD | -100.0% |
| 2015 Q3 | -2.31 Million AUD | -84.9% |
| 2015 Q4 | -4.63 Million AUD | -100.0% |
| 2015 Q1 | -626.34 Thousand AUD | 88.4% |
| 2014 Q2 | -7.92 Million AUD | -100.0% |
| 2014 FY | -13.32 Million AUD | -71.17% |
| 2014 Q3 | -2.7 Million AUD | 65.94% |
| 2014 Q1 | -3.96 Million AUD | -14.74% |
| 2014 Q4 | -5.4 Million AUD | -100.0% |
| 2013 Q3 | -1.72 Million AUD | 60.13% |
| 2013 Q4 | -3.45 Million AUD | -100.0% |
| 2013 Q1 | -2.16 Million AUD | 0.0% |
| 2013 FY | -7.78 Million AUD | -48.63% |
| 2013 Q2 | -4.33 Million AUD | -100.0% |
| 2012 FY | -5.23 Million AUD | 18.53% |
| 2011 FY | -6.43 Million AUD | -31.06% |
| 2010 FY | -4.9 Million AUD | 34.77% |
| 2009 FY | -7.52 Million AUD | 44.64% |
| 2008 Q1 | -5.04 Million AUD | -202.94% |
| 2008 FY | -13.58 Million AUD | -21.99% |
| 2008 Q4 | -1.74 Million AUD | 7.92% |
| 2008 Q3 | -1.9 Million AUD | 62.35% |
| 2008 Q2 | -5.04 Million AUD | 0.04% |
| 2007 FY | -11.14 Million AUD | 5.0% |
| 2007 Q4 | -1.66 Million AUD | 0.44% |
| 2007 Q3 | -1.67 Million AUD | 57.1% |
| 2007 Q2 | -3.9 Million AUD | -0.23% |
| 2007 Q1 | -3.89 Million AUD | -32.94% |
| 2006 Q3 | -2.93 Million AUD | -8.72% |
| 2006 Q2 | -2.69 Million AUD | -5.58% |
| 2006 Q1 | -2.55 Million AUD | 70.87% |
| 2006 FY | -11.72 Million AUD | 52.92% |
| 2006 Q4 | -2.92 Million AUD | 0.12% |
| 2005 Q3 | -8.91 Million AUD | -149.67% |
| 2005 Q4 | -8.76 Million AUD | 1.68% |
| 2005 FY | -24.9 Million AUD | -153.49% |
| 2005 Q2 | -3.57 Million AUD | -0.1% |
| 2005 Q1 | -3.56 Million AUD | -22.07% |
| 2004 Q4 | -2.92 Million AUD | 0.58% |
| 2004 Q1 | -2.01 Million AUD | 0.16% |
| 2004 FY | -9.82 Million AUD | -114.94% |
| 2004 Q3 | -2.94 Million AUD | -45.68% |
| 2004 Q2 | -2.01 Million AUD | 0.03% |
| 2003 Q4 | -2.02 Million AUD | -654.41% |
| 2003 Q1 | -1.62 Million AUD | 0.0% |
| 2003 Q2 | -1.56 Million AUD | 3.19% |
| 2003 FY | -4.57 Million AUD | 16.15% |
| 2003 Q3 | 364.8 Thousand AUD | 123.24% |
| 2002 FY | -5.45 Million AUD | -31.71% |
| 2001 FY | -4.13 Million AUD | -212.07% |
| 2000 FY | -1.32 Million AUD | -1557.86% |
| 1999 FY | -80 Thousand AUD | -11494.2% |
| 1998 FY | -690.00 AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AdAlta Limited | -5.38 Million AUD | -255.371% |
| Acrux Limited | -5.8 Million AUD | -229.715% |
| Botanix Pharmaceuticals Limited | -13.86 Million AUD | -37.879% |
| BTC Health Limited | 1.05 Million AUD | 1912.158% |
| Chimeric Therapeutics Limited | -12.52 Million AUD | -52.623% |
| Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 54.817% |
| Clinuvel Pharmaceuticals Limited | 35.63 Million AUD | 153.663% |
| Biome Australia Limited | -1.67 Million AUD | -1044.979% |
| Hexima Limited | -933.87 Thousand AUD | -1947.759% |
| Immutep Limited | -39.89 Million AUD | 52.067% |
| Memphasys Limited | -4.44 Million AUD | -330.513% |
| Neuren Pharmaceuticals Limited | 157.08 Million AUD | 112.174% |
| Noxopharm Limited | -3.57 Million AUD | -434.456% |
| Prescient Therapeutics Limited | -8.23 Million AUD | -132.136% |
| Race Oncology Limited | -13.81 Million AUD | -38.382% |
| Radiopharm Theranostics Limited | -47.94 Million AUD | 60.117% |
| Starpharma Holdings Limited | -8.16 Million AUD | -134.213% |
| Tissue Repair Ltd | -4.13 Million AUD | -362.131% |
| Biotron Limited | -3.43 Million AUD | -456.477% |
| CSL Limited | 2.64 Billion AUD | 100.724% |
| EZZ Life Science Holdings Limited | 6.96 Million AUD | 374.585% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -1217.731% |
| Bio-Gene Technology Limited | -2.4 Million AUD | -693.775% |
| Zelira Therapeutics Limited | -36.56 Million AUD | 47.706% |
| Patrys Limited | -3.53 Million AUD | -440.341% |
| Orthocell Limited | -7.18 Million AUD | -166.308% |
| Imugene Limited | -149.68 Million AUD | 87.224% |
| PYC Therapeutics Limited | -37.72 Million AUD | 49.309% |
| Proteomics International Laboratories Limited | -6.37 Million AUD | -199.919% |
| Cynata Therapeutics Limited | -9.74 Million AUD | -96.245% |
| Arovella Therapeutics Limited | -8.74 Million AUD | -118.653% |
| Nanollose Limited | -1.15 Million AUD | -1553.488% |
| Invex Therapeutics Ltd | -1.64 Million AUD | -1064.78% |
| NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | 5998.481% |
| Amplia Therapeutics Limited | -4.5 Million AUD | -324.64% |
| Island Pharmaceuticals Limited | -2.86 Million AUD | -567.645% |
| Nyrada Inc. | -1.38 Million AUD | -1279.533% |
| Telix Pharmaceuticals Limited | 5.21 Million AUD | 466.983% |
| Dimerix Limited | -17.07 Million AUD | -11.996% |
| PharmAust Limited | -9.03 Million AUD | -111.722% |
| AnteoTech Limited | -8.88 Million AUD | -115.342% |
| Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 67.396% |
| Recce Pharmaceuticals Ltd | -17.66 Million AUD | -8.276% |
| Avecho Biotechnology Limited | -3.43 Million AUD | -456.471% |
| Actinogen Medical Limited | -13.04 Million AUD | -46.604% |
| Immuron Limited | -6.93 Million AUD | -175.675% |
| Argenica Therapeutics Limited | -5.47 Million AUD | -249.001% |